JP Morgan Chase’s Cardiol Therapeutics CRDL Stock Holding History
Bought
Maintained
Sold
Other funds holding CRDL
MI
JP Morgan Chase's CRDL Position: Q3 2026 in Review
JP Morgan Chase held its Cardiol Therapeutics (CRDL) position steady in Q3 2026 at 48,077 shares worth $81.2K. The position accounts for ﹤0.01% of the portfolio, ranked #6332.
JP Morgan Chase first reported a position in CRDL in Q3 2024 and has held it in 4 quarters since. 59 funds tracked by Wall St. Rank hold CRDL as of Q3 2026.
- JP Morgan Chase held 48,077 shares of Cardiol Therapeutics worth $81.2K as of Q3 2026.
- JP Morgan Chase left its Cardiol Therapeutics share count unchanged in Q3 2026.
- Cardiol Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2026, its #6332 holding.
- JP Morgan Chase first reported a position in Cardiol Therapeutics in Q3 2024 and has held it in 4 quarters since.
- 59 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q3 2026.
Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.